Familial dysautonomia

Last updated
Familial dysautonomia
Other namesRiley–Day syndrome [1] and Hereditary sensory and autonomic neuropathy type III (HSAN-III)
Riley day.jpg
Facial features of a patient with familial dysautonomia over time: Note flattening of upper lip. By age 10, prominence of the lower jaw is apparent and by age 19 a mild erosion of right nostril occurs due to inadvertent self-mutilation.
Specialty Neurology   OOjs UI icon edit-ltr-progressive.svg

Familial dysautonomia (FD), also known as Riley-Day syndrome, is a rare, [2] progressive, [3] recessive genetic disorder of the autonomic nervous system [2] that affects the development and survival of sensory, sympathetic, and some parasympathetic neurons in the autonomic and sensory nervous system.

Contents

FD results in variable symptoms, including insensitivity to pain, inability to produce tears, poor growth, and labile blood pressure (episodic hypertension and postural hypotension). People with FD have frequent vomiting crises, pneumonia, problems with speech and movement, difficulty swallowing, and inappropriate perception of heat, pain and taste, as well as unstable blood pressure and gastrointestinal dysmotility.

Originally reported by Drs. Conrad Milton Riley and Richard Lawrence Day in 1949, [4] FD is one example of a group of disorders known as hereditary sensory and autonomic neuropathies (HSANs). [5] All HSANs are characterized by widespread sensory dysfunction and variable autonomic dysfunction caused by incomplete development of sensory and autonomic neurons. The disorders are believed to be genetically distinct from each other.

Signs and symptoms

Signs and symptoms of familial dysautonomia usually commence during infancy and worsen with age, and may include gastrointestinal dysmotility (including erratic gastric emptying, gastroesophageal reflux, abnormal esophageal peristalsis, oropharyngeal incoordination), [3] dysphagia (as poor suckling in infancy) and frequent choking/gagging, recurrent vomiting, poor weight gain [6] /growth, [7] delayed development (especially walking) and puberty (especially in girls), recurrent aspiration pneumonia (due to inhalation of food or vomitus) [6] with possible secondary chronic lung disease, [3] absence of overflow tears during crying, corneal ulcers, red skin blotches and excessive sweating (often during eating or excitement), breath-holding spells, slurred speech/nasal voice, tongue ulcers (from accidental self-injuries), hyporeflexia (variable absence of deep tendon reflexes [8] ), hypotonia, enuresis, arrhythmias, hypertension (including episodic hypertension in response to emotional stress or visceral pain [3] ), hypotension (including orthostatic hypertension [7] with compensatory tachycardia (invariably present) [3] ), [6] impaired (but not absent [3] ) temperature and pain perception (leading to frequent accidental injury), [2] [6] impaired proprioception, a smooth glossy tongue, [6] scoliosis (with possibly secondary restrictive lung disease [3] ), [7] abnormal gait, [9] short stature, chronic renal failure (common), visual impairment, variable cognitive ability, characteristic facial features that develop with time, impaired vibration perception, lack of fungiform papilla of the tongue, [3] and impaired taste perception (especially for sweetness). [8]

Progression

Familial dysautonomia presents with progressive, [3] age-specific symptoms.

Though usually not diagnosed until several years of age, generalised signs of FD are present during the newborn period in more than 80% of those affected. [8] Dysmorpnic facial features are not directly inherent to the disorder, but facial asymmetry and a straightened mouth eventually develop due to abnormal tone and molding of facial bones. [8] [3]

Perinatal

A very high incidence of breech presentation has been noted among infants with FD. [8] [10] [11] A lower birth weight as compared to siblings, [10] premature birth, and intrauterine growth restriction [8] have also been noted.

Neonatal

During the neonatal period, hypotonia, respiratory insufficiency, poor feeding with difficulty swallowing and aspiration, developmental delay, short stature, scoliosis, and corneal disease may occur. [8]

Infancy

Issues related to the disorder first appear during infancy. Early manifestations include hypotonia, feeding difficulty (impaired swallowing and suckling [2] ), poor growth, absence of tears, frequent lung infections, and poor body-temperature control (infants may display cold hands and feet [2] ). Developmental milestones (e.g. walking, speech) may or may not be delayed. [7]

In infants with FD, a lack of overflow tears during emotional crying may be noted after the age of 7 months (until this age, overflow emotional tearing may also not occur in unaffected infants; [12] overflow tearing is absent in neonates and begins to appear only after 2–3 months of age [8] ). [12]

Affected infants' hands may alternatively appear cool and mottled (from vasoconstriction), or red and swollen (from vasodilation). [8] Red skin blotching is often precipitated by emotional excitement. [8]

In older infants and young children, breath-holding spells may occur, possibly leading to cyanosis or fainting. Breath-holding behaviour usually ceases by age 6. [7]

Children

Kyphoscoliosis in a 10-year-old girl with HSANIII Kyphoscoliosis hereditary sensory autonomic neuropathy III.jpg
Kyphoscoliosis in a 10-year-old girl with HSANIII

Breath-holding behaviour usually resolves by age 6. In school-age children, bed wetting, vomiting episodes, impaired pain and temperature perception, impaired blood pressure control (including orthostatic hypotension, a hypertension during periods of psychological excitement or vomiting), learning disabilities (e.g. short attention span; learning disabilities are present in about a third of those with FD, and may require special education), scoliosis, poor bone quality and bone fractures, and kidney and heart issues may be seen. [7]

Adolescence and adulthood

Issues that tend to commence during adolescence or early adulthood include lung damage due to multiple respiratory infections, impaired kidney function, and impaired vision (due to atrophy of the optic nerve). [7] By adulthood, difficulties with balance and unaided walking often arise. [7]

Cause

Familial dysautonomia is the result of mutations in the IKBKAP gene on chromosome 9, which encodes for the IKAP protein (IkB kinase complex-associated protein). Three mutations in IKBKAP have been identified in individuals with FD. The most common FD-causing mutation occurs in intron 20 of the donor gene. Conversion of T→C in intron 20 of the donor gene resulted in shift splicing that generates an IKAP transcript lacking exon 20. Translation of this mRNA results in a truncated protein lacking all of the amino acids encoded by exons 20–37. Another less common mutation is a G→C conversion resulting in a one-amino-acid mutation in 696, where proline substitutes for normal arginine. The decreased amount of functional IKAP protein in cells causes familial dysautonomia.[ citation needed ]

Diagnosis

Clinical diagnosis

Autosomal recessive inheritance Autorecessive.svg
Autosomal recessive inheritance

A clinical diagnosis of FD is supported by a constellation of criteria:[ citation needed ]

Genetic testing

Genetic testing is performed on a small sample of blood from the tested individual. The DNA is examined with a designed probe specific to the known mutations. The accuracy of the test is above 99%. Dr. Anat Blumenfeld of the Hadassah Medical center in Jerusalem identified chromosome number 9 as the responsible chromosome.[ citation needed ]

Prenatal testing

Familial dysautonomia is inherited in an autosomal recessive pattern, which means two copies of the gene in each cell are altered. If both parents are shown to be carriers by genetic testing, a 25% chance exists that the child will have FD. For pregnancies at increased risk for FD, preimplantation genetic diagnosis or prenatal diagnosis by amniocentesis (at 15–17 weeks) or chorionic villus sampling (at 10–14 weeks) is possible.[ citation needed ]

Management

No cure for FD has been identified. The only two treatment centers are at New York University Hospital [13] and the Sheba Medical Center in Israel. [14] One is being planned for the San Francisco area. [15] Although the FD-causing gene has been identified and it seems to have tissue-specific expression, no definitive treatment exists at present.[ citation needed ]

A major issue has been aspiration pneumonia. Fundoplications (by preventing regurgitation) and gastrostomy tubes (to preclude oral nutrition) have reduced the frequency of hospitalization.[ citation needed ] Other issues that can be treated include FD crises, scoliosis, and various eye conditions due to limited or no tears.[ citation needed ]

Treatment of FD remains preventative, symptomatic, and supportive. FD does not express itself in a consistent manner. The types and severity of symptoms displayed vary among patients and even at different ages on the same patients, so patients should have specialized individual treatment plans. Medications are used to control vomiting, eye dryness, and abnormal blood pressure. Common management strategies include artificial tears, appropriate feeding strategy (maintenance of adequate nutrition, avoidance of aspiration (thickened formula and differently shaped nipples[ further explanation needed ] for infants)), daily chest physiotherapy (nebulization, bronchodilators, and postural drainage) for chronic pulmonary disease, pharmaceutical management of autonomic features (e.g. intravenous or rectal diazepam, or rectal chloral hydrate), preventing accidental injury, prevention of orthostatic hypotension (hydration, leg exercise, frequent small meals, a high-salt diet, and medication (e.g. with fludrocortisone)), treatment of orthopedic problems, compensating labile blood pressure.[ citation needed ]

Parents and patients should be informed regarding daily eye care and early signs of corneal problems, as well as punctal cautery. Informing patients and caretakers has resulted in decreased corneal scarring and need for more aggressive surgical measures such as tarsorrhaphy, conjunctival flaps, and corneal transplants.[ citation needed ]

Prognosis

Average age of death is in the third decade of life, but affected persons may live into their 70s. [3] Death occurs in 50% of the affected individuals by age 30. The outlook for patients with FD depends on the particular diagnostic category. Patients with chronic, progressive, generalized dysautonomia in the setting of central nervous system degeneration have a generally poor long-term prognosis. Death can occur from pneumonia, acute respiratory failure, or sudden cardiopulmonary arrest in such patients.[ citation needed ]

The survival rate and quality of life have increased since the mid-1980s, mostly due to a greater understanding of the most dangerous symptoms. At present, FD patients can be expected to function independently if treatment is begun early and if major disabilities are avoided.[ citation needed ]

Epidemiology

Familial dysautonomia is seen almost exclusively in Ashkenazi Jews and is inherited in an autosomal recessive fashion. Both parents must be carriers for a child to be affected. The carrier frequency in Jews of Eastern and Central European (Ashkenazi) ancestry is about one in 30, while the carrier frequency in non-Jews is unknown. If both parents are carriers, a one in four chance exists with each pregnancy for an affected child. Genetic counseling and genetic testing are recommended for families who may be carriers of familial dysautonomia.[ citation needed ]

Worldwide, about 600 diagnoses have been recorded since discovery of the disease, with around 350 of them still living. [16]

Research

In January 2001, researchers at Fordham University and Massachusetts General Hospital simultaneously reported finding the genetic mutation that causes FD, a discovery that opens the door to many diagnostic and treatment possibilities. [17] [18] Genetic screening subsequently became available in 2001, enabling Ashkenazi Jews to find out if they are carriers.[ citation needed ]

Stem-cell therapy has been proposed as a potential future treatment. Eventually, treatment could be given in utero.[ citation needed ] Research into treatments is being funded by foundations organized and run by parents of those with FD. No governmental support has been given beyond recognizing those diagnosed with FD as eligible for certain programs. [19]

See also

Related Research Articles

Orthostatic hypotension, also known as postural hypotension, is a medical condition wherein a person's blood pressure drops when standing up or sitting down. Primary orthostatic hypotension is also often referred to as neurogenic orthostatic hypotension. The drop in blood pressure may be sudden, within 3 minutes or gradual. It is defined as a fall in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg after 3 mins of standing. It occurs predominantly by delayed constriction of the lower body blood vessels, which is normally required to maintain adequate blood pressure when changing the position to standing. As a result, blood pools in the blood vessels of the legs for a longer period, and less is returned to the heart, thereby leading to a reduced cardiac output and inadequate blood flow to the brain.

<span class="mw-page-title-main">Autonomic neuropathy</span> Medical condition

Autonomic neuropathy is a form of polyneuropathy that affects the non-voluntary, non-sensory nervous system, affecting mostly the internal organs such as the bladder muscles, the cardiovascular system, the digestive tract, and the genital organs. These nerves are not under a person's conscious control and function automatically. Autonomic nerve fibers form large collections in the thorax, abdomen, and pelvis outside the spinal cord. They have connections with the spinal cord and ultimately the brain, however. Most commonly autonomic neuropathy is seen in persons with long-standing diabetes mellitus type 1 and 2. In most—but not all—cases, autonomic neuropathy occurs alongside other forms of neuropathy, such as sensory neuropathy.

<span class="mw-page-title-main">Dysautonomia</span> Any disease or malfunction of the autonomic nervous system

Dysautonomia or autonomic dysfunction is a condition in which the autonomic nervous system (ANS) does not work properly. This may affect the functioning of the heart, bladder, intestines, sweat glands, pupils, and blood vessels. Dysautonomia has many causes, not all of which may be classified as neuropathic. A number of conditions can feature dysautonomia, such as Parkinson's disease, multiple system atrophy, dementia with Lewy bodies, Ehlers-Danlos syndromes, autoimmune autonomic ganglionopathy and autonomic neuropathy, HIV/AIDS, autonomic failure, and postural orthostatic tachycardia syndrome.

<span class="mw-page-title-main">Hypotension</span> Abnormally low blood pressure

Hypotension is low blood pressure. Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps out blood. Blood pressure is indicated by two numbers, the systolic blood pressure and the diastolic blood pressure, which are the maximum and minimum blood pressures, respectively. A systolic blood pressure of less than 90 millimeters of mercury (mmHg) or diastolic of less than 60 mmHg is generally considered to be hypotension. Different numbers apply to children. However, in practice, blood pressure is considered too low only if noticeable symptoms are present.

<span class="mw-page-title-main">Alport syndrome</span> Medical condition

Alport syndrome is a genetic disorder affecting around 1 in 5,000-10,000 children, characterized by glomerulonephritis, end-stage kidney disease, and hearing loss. Alport syndrome can also affect the eyes, though the changes do not usually affect vision, except when changes to the lens occur in later life. Blood in urine is universal. Proteinuria is a feature as kidney disease progresses.

<span class="mw-page-title-main">Lesch–Nyhan syndrome</span> Rare genetic disorder

Lesch–Nyhan syndrome (LNS) is a rare inherited disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). This deficiency occurs due to mutations in the HPRT1 gene located on the X chromosome. LNS affects about 1 in 380,000 live births. The disorder was first recognized and clinically characterized by American medical student Michael Lesch and his mentor, pediatrician William Nyhan, at Johns Hopkins.

<span class="mw-page-title-main">Congenital insensitivity to pain with anhidrosis</span> Medical condition

Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive disorder of the nervous system which prevents the feeling of pain or temperature, and prevents a person from sweating. Cognitive disorders are commonly coincident. CIPA is the fourth type of hereditary sensory and autonomic neuropathy (HSAN), and is also known as HSAN IV.

Norrie disease is a rare disease and genetic disorder that primarily affects the eyes and almost always leads to blindness. It is caused by mutations in the Norrin cystine knot growth factor (NDP) gene, which is located on the X chromosome. In addition to the congenital ocular symptoms, the majority of patients experience a progressive hearing loss starting mostly in their 2nd decade of life, and some may have learning difficulties among other additional characteristics.

IKBKAP is a human gene encoding the IKAP protein, which is ubiquitously expressed at varying levels in all tissue types, including brain cells. The IKAP protein is thought to participate as a sub-unit in the assembly of a six-protein putative human holo-Elongator complex, which allows for transcriptional elongation by RNA polymerase II. Further evidence has implicated the IKAP protein as being critical in neuronal development, and directs that decreased expression of IKAP in certain cell types is the molecular basis for the severe, neurodevelopmental disorder familial dysautonomia. Other pathways that have been connected to IKAP protein function in a variety of organisms include tRNA modification, cell motility, and cytosolic stress signalling. Homologs of the IKBKAP gene have been identified in multiple other Eukaryotic model organisms. Notable homologs include Elp1 in yeast, Ikbkap in mice, and D-elp1 in fruit flies. The fruit fly homolog (D-elp1) has RNA-dependent RNA polymerase activity and is involved in RNA interference.

Lecithin cholesterol acyltransferase deficiency is a disorder of lipoprotein metabolism. The disease has two forms: Familial LCAT deficiency, in which there is complete LCAT deficiency, and Fish-eye disease, in which there is a partial deficiency.

Hereditary sensory and autonomic neuropathy (HSAN) or hereditary sensory neuropathy (HSN) is a condition used to describe any of the types of this disease which inhibit sensation.

<span class="mw-page-title-main">Dopamine beta hydroxylase deficiency</span> Medical condition

Dopamine beta (β)-hydroxylase deficiency is a condition involving inadequate dopamine beta-hydroxylase. It is characterized by increased amounts of serum dopamine and the absence of norepinephrine (NE) and epinephrine. Dopamine is released, as a false neurotransmitter, in place of norepinephrine. Other names for norepinephrine include noradrenaline (NA) and noradrenalin. This condition is also sometimes referred to as "norepinephrine deficiency". Researchers of disorders such as schizophrenia are interested in studying this disorder, as patients with these specific diseases can have an increase in the amount of dopamine in their system and yet do not show other symptoms of DβH deficiency.

<span class="mw-page-title-main">Sotos syndrome</span> Genetic overgrowth disorder

Sotos syndrome is a rare genetic disorder characterized by excessive physical growth during the first years of life. Excessive growth often starts in infancy and continues into the early teen years. The disorder may be accompanied by autism, mild intellectual disability, delayed motor, cognitive, and social development, hypotonia, and speech impairments. Children with Sotos syndrome tend to be large at birth and are often taller, heavier, and have relatively large skulls (macrocephaly) than is normal for their age. Signs of the disorder, which vary among individuals, include a disproportionately large skull with a slightly protrusive forehead, large hands and feet, large mandible, hypertelorism, and downslanting eyes. Clumsiness, an awkward gait, and unusual aggressiveness or irritability may also occur.

Heat intolerance is a symptom characterized by feeling overheated in warm environments or when the surrounding environment's temperature rises. Typically, the person feels uncomfortably hot and sweats excessively.

Orthostatic hypertension is a medical condition consisting of a sudden and abrupt increase in blood pressure (BP) when a person stands up. Orthostatic hypertension is diagnosed by a rise in systolic BP of 20 mmHg or more when standing. Orthostatic diastolic hypertension is a condition in which the diastolic BP raises to 98 mmHg or over in response to standing, but this definition currently lacks clear medical consensus, so is subject to change. Orthostatic hypertension involving the systolic BP is known as systolic orthostatic hypertension.

<span class="mw-page-title-main">Floating–Harbor syndrome</span> Medical condition

Floating–Harbor syndrome, also known as Pelletier–Leisti syndrome, is a rare disease with fewer than 50 cases described in the literature. It is usually diagnosed in early childhood and is characterized by the triad of proportionate short stature with delayed bone age, characteristic facial appearance, and delayed speech development. Although its cause is unknown, it is thought to result from genetic mutation, and diagnosis is established by the presence of a heterozygous SRCAP mutation in those with clinical findings of FHS.

Hereditary sensory and autonomic neuropathy type I or hereditary sensory neuropathy type I is a group of autosomal dominant inherited neurological diseases that affect the peripheral nervous system particularly on the sensory and autonomic functions. The hallmark of the disease is the marked loss of pain and temperature sensation in the distal parts of the lower limbs. The autonomic disturbances, if present, manifest as sweating abnormalities.

<span class="mw-page-title-main">Primary juvenile glaucoma</span> Medical condition

Primary juvenile glaucoma is glaucoma that develops due to ocular hypertension and is evident either at birth or within the first few years of life. It is caused due to abnormalities in the anterior chamber angle development that obstruct aqueous outflow in the absence of systemic anomalies or other ocular malformation.

<span class="mw-page-title-main">Okamoto syndrome</span> Rare genetic condition involving urinary, heart, facial and neurological features

Okamoto syndrome (OS), also known as Au–Kline syndrome (AKS), is a very rare autosomal dominant genetic condition characterised by congenital hydronephrosis, low muscle tone, heart defects, intellectual disability and characteristic facial features. Those affected often have neurological and skeletal abnormalities, as well as frequent urinary tract infections. Language and walking are usually delayed. Facial features include prominent, downturned ears, an open, downturned mouth and drooping eyelids (ptosis).

<span class="mw-page-title-main">Adolescent idiopathic scoliosis</span> Medical condition

Adolescent idiopathic scoliosis is a rather common disorder in which the spine starts abnormally curving sideways (scoliosis) at the age of 10–18 years old. This disorder generally occurs during the growth spurt that happens right before and during adolescence. In some teens, the curvature is progressive, meaning that it gets worse over time, however this is rare, since it is more common for this variant of scoliosis to show itself as a mild curvature.

References

  1. pediatriconcall.com Archived 2007-04-30 at the Wayback Machine
  2. 1 2 3 4 5 "Dysautonomia, Familial". NORD (National Organization for Rare Disorders). Retrieved 2020-05-31.
  3. 1 2 3 4 5 6 7 8 9 10 11 "Orphanet: Familial dysautonomia". www.orpha.net. Retrieved 2020-05-31.
  4. Riley CM, Day RL, Greely D, Langford WS (1949). "Central autonomic dysfunction with defective lacrimation". Pediatrics. 3 (4): 468–77. doi:10.1542/peds.3.4.468. PMID   18118947. S2CID   245200408.
  5. Axelrod FB (2002). "Hereditary sensory and autonomic neuropathies. Familial dysautonomia and other HSANs". Clin Auton Res. 12. Suppl 1 (7): I2–14. doi:10.1007/s102860200014. PMID   12102459. S2CID   44306353.
  6. 1 2 3 4 5 6 Publishing, Harvard Health (21 December 2018). "Familial Dysautonomia". Harvard Health. Retrieved 2020-05-30.
  7. 1 2 3 4 5 6 7 8 Reference, Genetics Home. "Familial dysautonomia". Genetics Home Reference. Retrieved 2020-05-30.
  8. 1 2 3 4 5 6 7 8 9 10 11 12 Neonatal and infant dermatology. Eichenfield, Lawrence F.,, Frieden, Ilona J.,, Mathes, Erin F.,, Zaenglein, Andrea L. (Third ed.). London. 5 September 2014. ISBN   978-1-4557-2639-4. OCLC   885376300.{{cite book}}: CS1 maint: location missing publisher (link) CS1 maint: others (link)
  9. Portnoy, Sigal; Maayan, Channa; Tsenter, Jeanna; Ofran, Yonah; Goldman, Vladimir; Hiller, Nurit; Karniel, Naama; Schwartz, Isabella (2018-04-26). "Characteristics of ataxic gait in familial dysautonomia patients". PLOS ONE. 13 (4): e0196599. Bibcode:2018PLoSO..1396599P. doi: 10.1371/journal.pone.0196599 . ISSN   1932-6203. PMC   5919612 . PMID   29698477.
  10. 1 2 Axelrod, Felicia B.; Leistner, Hedi L.; Porges, Robert F. (1974-01-01). "Breech presentation among infants with familial dysautonomia". The Journal of Pediatrics. 84 (1): 107–109. doi:10.1016/S0022-3476(74)80564-0. ISSN   0022-3476. PMID   12119926.
  11. Mostello, D.; Chang, J. J.; Bai, F.; Wang, J.; Guild, C.; Stamps, K.; Leet, T. L. (January 2014). "Breech presentation at delivery: a marker for congenital anomaly?". Journal of Perinatology. 34 (1): 11–15. doi: 10.1038/jp.2013.132 . ISSN   1476-5543. PMID   24157495. S2CID   21579907.
  12. 1 2 "Familial Dysautonomia Workup: Laboratory Studies". emedicine.medscape.com. Retrieved 2020-05-31.
  13. Dysautonomia Treatment and Evaluation Center Archived 2006-01-14 at the Wayback Machine
  14. Sheba Medical Center
  15. "San Francisco To Get a Genetics Center - Forward.com". 5 August 2005. Retrieved 2007-11-02.
  16. "FD History & Statistics - Dysautonomia Foundation - Familial Dysautonomia (FD)". Archived from the original on 2009-04-18. Retrieved 2009-04-02.
  17. Anderson SL, Coli R, Daly IW, Kichula EA, Rork MJ, Volpi SA, Ekstein J, Rubin BY (2001). "Familial dysautonomia is caused by mutations of the IKAP gene". Am J Hum Genet. 68 (3): 753–8. doi:10.1086/318808. PMC   1274486 . PMID   11179021.
  18. Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF (2001). "Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia". Am J Hum Genet. 68 (3): 598–605. doi:10.1086/318810. PMC   1274473 . PMID   11179008.
  19. Benefits for people with FD Archived 2011-07-26 at the Wayback Machine – from Dysautonomia foundation

Further reading